Header
Carmel Pharma ab
Market
PhaSeal is today a global product established in many countries around the world.
Click here to learn more...
Vision & Mission
Our vision is to remain the world leader in closed drug transfer systems.
Click here to learn more...
Investor Relations
Annual Reports, Members of the Board, Executive Management.

Carmel Update

Interim report Jan-June 2008

• Income for the period amounted to KSEK 103,657 (89,582)
• Sales increased by 28 percent in fixed currencies
• The consolidated net profit after tax for the first six months of the year amounted to
KSEK 6,003 (5,694)
• Earnings per share before dilution were SEK 0.76 (0.72) for the period
• Available liquid funds: KSEK 15,826 (12,921)

Download
Disclaimer
Copyright © 2007 Carmel Pharma ab. All rights Reserved